Trial Outcomes & Findings for Polypharmacy and Outcomes After Elective Noncardiac Surgery (NCT NCT03133182)

Results Overview

death from any cause

Recruitment status

COMPLETED

Target enrollment

266499 participants

Primary outcome timeframe

from day of surgery up to 90 days after surgery

Results posted on

2025-01-24

Participant Flow

Participant milestones

Participant milestones
Measure	Polypharmacy People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy People taking \<5 unique prescription drugs in the 3 months prior to surgery
Overall Study STARTED	146029	120470
Overall Study COMPLETED	146029	120470
Overall Study NOT COMPLETED	0	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Polypharmacy and Outcomes After Elective Noncardiac Surgery

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Polypharmacy n=146029 Participants People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy n=120470 Participants People taking \<5 unique prescription drugs in the 3 months prior to surgery	Total n=266499 Participants Total of all reporting groups
Age, Continuous	75 years STANDARD_DEVIATION 6 • n=99 Participants	73 years STANDARD_DEVIATION 6 • n=107 Participants	74 years STANDARD_DEVIATION 6 • n=206 Participants
Sex: Female, Male Female	81922 Participants n=99 Participants	59512 Participants n=107 Participants	141434 Participants n=206 Participants
Sex: Female, Male Male	64107 Participants n=99 Participants	60958 Participants n=107 Participants	125065 Participants n=206 Participants
Income quintile	3 Income group n=99 Participants	3 Income group n=107 Participants	3 Income group n=206 Participants

PRIMARY outcome

Timeframe: from day of surgery up to 90 days after surgery

death from any cause

Outcome measures

Outcome measures
Measure	Polypharmacy n=146029 Participants People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy n=120470 Participants People taking \<5 unique prescription drugs in the 3 months prior to surgery
Mortality	4356 Participants	1919 Participants

SECONDARY outcome

Timeframe: From day of surgery to day of hospital discharge, up to 365 days after surgery

Patient with a complication based on clusters of ICD-10 Type 2 codes collected in the hospital record

Outcome measures

Outcome measures
Measure	Polypharmacy n=146029 Participants People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy n=120470 Participants People taking \<5 unique prescription drugs in the 3 months prior to surgery
Complications	31570 Participants	19815 Participants

SECONDARY outcome

Timeframe: date of surgery to date of hospital discharge, or 365 days after surgery, whichever comes first

Number of days in hospital after surgery

Outcome measures

Outcome measures
Measure	Polypharmacy n=146029 Participants People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy n=120470 Participants People taking \<5 unique prescription drugs in the 3 months prior to surgery
Length of Stay	5 Days Interval 4.0 to 8.0	5 Days Interval 3.0 to 7.0

SECONDARY outcome

Timeframe: date of surgery up to 90 days after surgery

Costs related to medical care paid for by the provincial health insurance system

Outcome measures

Outcome measures
Measure	Polypharmacy n=146029 Participants People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy n=120470 Participants People taking \<5 unique prescription drugs in the 3 months prior to surgery
Costs of Care	24064 Canadian Dollars Standard Deviation 16624	20251 Canadian Dollars Standard Deviation 24424

SECONDARY outcome

Timeframe: date of surgery to date of hospital discharge, or 365 days after surgery, whichever comes first

A discharge location at the end of the surgical episode of care that is not back to the patient's original residence (specifically respite or long term care)

Outcome measures

Outcome measures
Measure	Polypharmacy n=146029 Participants People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy n=120470 Participants People taking \<5 unique prescription drugs in the 3 months prior to surgery
Institutional Discharge	34128 Participants	23098 Participants

SECONDARY outcome

Timeframe: From the date of hospital discharge to 30 days after the date of discharge

Acute hospital readmission after discharge from index hospitalization

Outcome measures

Outcome measures
Measure	Polypharmacy n=146029 Participants People taking \>=5 unique prescription drugs in the 3 months prior to surgery Polypharmacy: Patients who are taking \>=5 unique prescription drugs in the 3 months prior to surgery	No Polypharmacy n=120470 Participants People taking \<5 unique prescription drugs in the 3 months prior to surgery
Hospital Readmission	13202 Participants	8097 Participants

Adverse Events

Polypharmacy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 4356 deaths

No Polypharmacy

Serious events: 0 serious events

Other events: 0 other events

Deaths: 1919 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Daniel McIsaac

The Ottawa Hospital

Phone: 613-761-4940

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place